


Bunyan DJ, Baker KR, Harvey JF, Thomas NS. Diagnostic screening identifies a wide range of mutations involving the SHOX gene, including a common 47.5kb deletion 160kb downstream with a variable phenotypic effect. Am J Med Genet 2013 161A:1329-1338.


Callaway JLA, Shaffer LG, Chitty LS, Rosenfeld JA, Crolla JA. The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: a review of the literature. Prenatal Diagnosis 2013 33:1119-1123


Chase A, Bryant C, Score J, Cross NCP. Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica 2013 98:103-106


Dixit A, Chandler KE, Lever M, Poole RL, Bullman H, Mughal MZ, Steggall M, Suri M. Pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q. J Clin Endocrinol Metab 2013 98: e103-8


Jacobs PA. Retrospective and prospective epidemiological studies of 1,500 karyotyped spontaneous human abortions. *Birth Defects Research (Part 1): Correspondence;* 2013 **97**:487-488


Jones AV, Cross NCP. Inherited predisposition to myeloproliferative neoplasms. *Ther Adv Hematol* 2013 **4**:237-253


Vorechovsky I, Jones AV, Cross NCP. Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms? 2013 **27**:1930-2

Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, Ross FM, Davies FE, Gonzalez D, Morgan GJ. Characterization of IgH breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pre-germinal center B cells. *Blood* 2013 **121**:3413-19

Walker BA, Wardell CP, Ross FM, Morgan GJ. Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR. *Genes Chromosomes Cancer* 2013 **52**:817-22


